Truist Financial
CYTK icon

Truist Financial’s Cytokinetics CYTK Stock Holding History

Truist Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,093
Closed -$597K – 2706
2021
Q4 		$597K Sell
13,093
-41
-0.3% -$1.58K ﹤0.01% 1918
2021
Q3 		$470K Sell
13,134
-19
-0.1% -$559 ﹤0.01% 2040
2021
Q2 		$260K Sell
13,153
-15
-0.1% -$352 ﹤0.01% 2452
2021
Q1 		$306K Buy
13,168
+828
+7% +$17.7K ﹤0.01% 2273
2020
Q4 		$256K Buy
12,340
+152
+1% +$2.78K ﹤0.01% 2250
2020
Q3 		$264K Buy
12,188
+2,941
+32% +$68.8K ﹤0.01% 2107
2020
Q2 		$218K Buy
+9,247
New +$173K ﹤0.01% 2136

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Truist Financial's CYTK Position: Q1 2022 in Review

Truist Financial sold out of Cytokinetics (CYTK) in Q1 2022, closing a stake of 13,093 shares — an estimated $597K sold.

Truist Financial first reported a position in CYTK in Q2 2020 and held it in 7 quarters. The position peaked at $597K in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

  • Truist Financial reported no remaining Cytokinetics position as of Q1 2022 after selling out during the quarter.
  • Truist Financial sold 13,093 Cytokinetics shares in Q1 2022, an estimated $597K.
  • Truist Financial first reported a position in Cytokinetics in Q2 2020 and held it in 7 quarters.
  • Truist Financial's Cytokinetics position peaked at $597K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.